Leung Keith, Saif Muhammad Wasif
Division of Hematology/Oncology, Department of Medicine and Cancer Center, Tufts Medical Center, Boston, MA 02111, USA.
JOP. 2013 Mar 10;14(2):149-51. doi: 10.6092/1590-8577/1462.
Pancreatic cancer is one of the deadliest cancers. While BRCA-associated pancreatic cancers are uncommon, the distinctive phenotype of this malignancy may offer unique therapeutic targets. At the 2013 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, a review of the characteristics and outcomes of one large case series (Abstract #278), however, did not reveal a benefit to first-line platinum chemotherapy in the treatment of advanced pancreatic cancer. In another study (Abstract #147), substantial responses were observed in both patients with BRCA2-associated pancreatic cancer treated with the poly-(ADP-ribose) polymerase (PARP) inhibitor ABT-888 (veliparib). We will review these abstracts and our current knowledge of the treatment for patients with BRCA-associated pancreatic cancer. In this group of patients, these new results continue to shape our understanding of this disease.
胰腺癌是最致命的癌症之一。虽然与BRCA相关的胰腺癌并不常见，但这种恶性肿瘤独特的表型可能提供独特的治疗靶点。然而，在2013年美国临床肿瘤学会（ASCO）胃肠道癌症研讨会上，对一个大型病例系列的特征和结果进行的回顾（摘要#278）并未显示一线铂类化疗对晚期胰腺癌的治疗有获益。在另一项研究（摘要#147）中，使用聚（ADP - 核糖）聚合酶（PARP）抑制剂ABT - 888（维利帕尼）治疗的BRCA2相关胰腺癌患者均观察到显著反应。我们将回顾这些摘要以及我们目前对BRCA相关胰腺癌患者治疗的认识。在这组患者中，这些新结果继续影响着我们对这种疾病的理解。
